Myriad Genetics Submits First Module of Premarket Approval Application to FDA for myChoice HRD CDx Test

Myriad Genetics Submits First Module of Premarket Approval Application to FDA for myChoice® HRD CDx Test

Myriad Genetics (NASDAQ:MYGN) has announced it has submitted the first module of its premarket approval (PMA) application to the US Food and Drug Administration (FDA) for the myChoice HRD CDx test. As quoted in the press release: Myriad is submitting myChoice HRD as a companion diagnostic for the identification of patients with ovarian, fallopian or … Continued

More From BioPortfolio on "Myriad Genetics Submits First Module of Premarket Approval Application to FDA for myChoice® HRD CDx Test"